Skip to Content

Intersect ENT, Inc. (NASDAQ: XENT)

Securities Class Action

  • Date:
  • 9/18/2019
  • Company Name:
  • Intersect ENT, Inc.
  • Stock Symbol:
  • XENT
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

NEW YORK, September 18, 2019 –Bragar Eagel and Squire is investigating certain officers and directors of Intersect ENT, Inc. (NYSE: XENT) following a class action complaint that was filed against Intersect ENT on May 15, 2019.

The complaint alleges that throughout the class period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company lacked adequate reimbursement representatives to ensure physicians had access to SINUVA; (2) that, as a result, the company's sales force would focus on ensuring reimbursement; (3) that, as a result, the company's sales representatives were less focused on driving sales; (4) that physicians were less likely to adopt the company's SINUVA due to transaction costs associated with seeking reimbursement; (5) that the company would increase staffing to address these issues; and (6) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are a long term stockholder of Intersect ENT continuously holding shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Intersect ENT. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: